(1 - 12 von 26
)
Pharma giant Valeant looking more desperate than ever
nypost.com
Irina Koffler, an analyst with Mizuho Securities USA, fretted that Valeant's business is so bad that it may not have any option other than to ...
Valeant at 80% buy shows how hard skepticism is for Wall Street - The...
www.theglobeandmail.com
It’s not hard to see why so few people covering the biotech company have been bearish
Mizuho Securities USA Announces Senior US Equity Research Appointment...
www.wallstreet-online.de
... the U.S. investment banking subsidiary of Mizuho Financial Group (NYSE: MFG), has appointed Irina Koffler Managing Director and Senior Analyst leading ...
AstraZeneca Potassium Drug Rejected; Rival Relypsa Roars | Investor's...
www.investors.com
The FDA rejected AstraZeneca's ZS-9 for hyperkalemia, raising hopes for Relypsa's slow-launching rival.
Because they’re worth it? L’Oréal to pay $1.3bn for Valeant brands –...
www.irishtimes.com
Canadian drug firm also to sell Dendreon unit for $820m to pay down $30bn in debt
FDA warns Valeant of issues at B+L plant
eu.democratandchronicle.com
Food and Drug Administration says there are quality control issues at the Rochester plant.
Troubled Drugmaker Valeant Seeks New CEO; Ackman Joins Board
www.newsweek.com
A board committee said its five-month investigation found broad accounting problems dating back to December
Stockwatch
www.stockwatch.com
No Hype - just the Facts. Your complete source of news and realtime quotes from the TSX, TSX-V, CSE, Montreal, Nasdaq, NYSE, Amex and OTC Markets.
UPDATE 3-Valeant predicts tough with revenue to decline |
www.kitco.com
"It still doesn't appear that management has a realistic outlook on its organic growth," Mizuho analyst Irina Koffler wrote in a research note.
Valeant CEO out, investor Ackman in over drugmaker's accounting...
www.businessinsurance.com
... weak and eroding, and do not expect a new management team to return the business to growth," Mizuho analyst Irina Koffler wrote in a note.
Valeant Rises As Analyst Admits 'Short Thesis Debunked' | Stock News...
www.investors.com
Valeant will probably escape disaster by wiggling out of its debt covenants, writes Mizuho.
sortiert nach Relevanz / Datum